A Seven-Year Retrospective Study on the Surveillance of Hepatitis B in Laos

Table 1

Type of drugs, number, and % on total and dual treatments.

Dual therapies	Nb	% of total treatment ()	% of dual therapy; ()
Cycloferon + Adefovir	55	7.9%	43.3%
Cycloferon + Lamivudine	42	6.1%	33.0%
Adefovir + Lamivudine	9	1.3%	7.1%
Cycloferon + Tenofovir	5	0.7%	4.0%
Tenofovir + Adefovir	4	0.6%	3.2%
Tenofovir + Lamivudine	4	0.6%	3.2%
Pegasys + Tenofovir	3	0.4%	2.4%
Pegasys + Adefovir	2	0.3%	1.6%
Entecavir + Tenofovir	1	0.1%	0.8%
Interferon + Cycloferon	1	0.1%	0.8%
Entecavir + Pegasys	1	0.1%	0.8%
Total	126	18.2%